4 June 2026 - Teva Pharmaceutical Industries today announced the launch of Ahzantive (aflibercept), a biosimilar to Eylea, in Europe further strengthening the Company’s growing biosimilars portfolio and expanding its presence in ophthalmology. 

The launch reflects Teva’s strategy to build a leading biosimilars business in areas of significant patient need and to broaden access to biologic medicines through strong partnerships, broad commercial capabilities, and reliable supply.

Read Teva Pharmaceuticals press release